We can’t show the full text here under this license. Use the link below to read it at the source.
Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial
Long-term effects of once-weekly semaglutide compared to other treatments in US adults with type 2 diabetes
AI simplified
Abstract
In a 2-year trial, 49.9% of participants treated with achieved (HbA)<7.0% at year 2 compared to 38.9% receiving alternative treatment.
- Semaglutide was associated with significantly higher proportions of participants achieving HbA<7.0% at both year 1 and year 2 compared to alternative treatments.
- Mean HbA decreases were greater in the semaglutide group at year 1 and year 2 compared to those on alternative treatment.
- Participants treated with semaglutide experienced larger reductions in body weight at year 1, but not at year 2.
- Treatment changes were less frequent with semaglutide than with alternative treatments.
- Some patient-reported outcomes indicated greater improvement in the semaglutide group compared to alternative treatments.
- No new safety concerns were identified during the trial.
AI simplified
Key numbers
53.1%
Increase in <7.0%
At year 1, 53.1% of participants reached <7.0%, vs. 45.5% for alternatives.
-1.35%
Mean reduction
At year 1, mean reduction was -1.35% for vs. -1.16% for alternatives.
-3.57%
Weight loss percentage
At year 1, body weight change was -3.57% for vs. -1.91% for alternatives.